1-cyclohexyl-3-phenethylurea | 70243-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-cyclohexyl-3-phenethylurea
• 英文别名: 1-Cyclohexyl-3-(2-phenylethyl)urea
• CAS: 70243-17-3
• 化学式: C₁₅H₂₂N₂O
• mdl: MFCD00815969
• 分子量: 246.352
• InChiKey: YJAMPQZPTKVFIU-UHFFFAOYSA-N

物化性质

• 熔点：
  122-123 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  454.7±15.0 °C(Predicted)
• 密度：
  1.06±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.533
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-(phenethylamino)-2-oxoacetic acid 在 collidine 作用下， 以 乙腈 为溶剂， 反应 18.0h， 生成 1-cyclohexyl-3-phenethylurea
  参考文献：
  名称：

  支持无电解质的草酸阳极氧化为异氰酸酯：一种获得尿素、氨基甲酸酯和硫代氨基甲酸酯的便捷方法

  摘要：

  我们报告了一种新的电化学无负载电解质方法，用于通过草酸氧化合成尿素、氨基甲酸酯和硫代氨基甲酸酯。这种简单、实用且无光气的路线包括在有机碱存在下通过草酸的阳极脱羧原位生成异氰酸酯中间体，然后一锅加入合适的亲核试剂以提供相应的尿素，氨基甲酸酯和硫代氨基甲酸酯。此程序适用于不同的胺、醇和硫醇。此外，当使用单程连续电化学流动条件并且该反应在碳石墨 C gr /C gr 在流动池中，可以在 6 分钟的停留时间内以高产率获得尿素化合物，解锁在批量条件下无法访问的底物，同时易于扩展。

  DOI：

  10.1021/acs.oprd.1c00112

文献信息

• Copper(II) Reagent-Promoted Degradation of<i>N</i>,<i>N</i>′-dialkyldiazenedicarboxamides
  作者：Jun-ichi Yamaguchi、Yukihito Murayama、Takayuki Suyama

  DOI：10.1246/bcsj.75.329

  日期：2002.2

  Degradation of N,N′-dialkyldiazenedicarboxamides with a copper(II) reagent, which was prepared from lithium 4-nitrophenoxide and copper(II) bromide in tetrahydrofuran, proceeded via formation of isocyanate to produce the corresponding 4-nitrophenyl N-alkylcarbamate with the evolution of nitrogen. Further, it was also found that 4-nitrophenyl N-alkylcarbamate reacted with primary or secondary amines

  N,N'-二烷基二氮杂二甲酰胺用铜（II）试剂降解，铜（II）试剂由 4-硝基苯氧基锂和溴化铜（II）在四氢呋喃中制备，通过形成异氰酸酯进行，产生相应的 4-硝基苯基 N-烷基氨基甲酸酯氮的演变。此外，还发现4-硝基苯基N-烷基氨基甲酸酯与伯胺或仲胺反应得到相应的多取代脲。基于上述结果，我们开发了一种从 N,N'-二烷基二氮杂二甲酰胺一锅法制备多取代脲的新方法。
• Structural Optimization of Berberine as a Synergist to Restore Antifungal Activity of Fluconazole against Drug-Resistant<i>Candida albicans</i>
  作者：Hong Liu、Liang Wang、Yan Li、Jiang Liu、Maomao An、Shaolong Zhu、Yongbing Cao、Zhihui Jiang、Mingzhu Zhao、Zhan Cai、Li Dai、Tingjunhong Ni、Wei Liu、Simin Chen、Changqing Wei、Chengxu Zang、Shujuan Tian、Jingyu Yang、Chunfu Wu、Dazhi Zhang、Hua Liu、Yuanying Jiang

  DOI：10.1002/cmdc.201300332

  日期：2014.1

  We have conducted systematic structural modification, deconstruction, and reconstruction of the berberine core with the aim of lowering its cytotoxicity, investigating its pharmacophore, and ultimately, seeking novel synergistic agents to restore the effectiveness of fluconazole against fluconazole‐resistant Candida albicans. A structure–activity relationship study of 95 analogues led us to identify

  我们已经对黄连素核心进行了系统的结构修饰，解构和重建，以降低其小toxic碱的细胞毒性，研究其药效团，并最终寻求新型协同剂以恢复氟康唑对耐氟康唑的白色念珠菌的有效性。通过对95个类似物的构效关系研究，我们确定了N-（2-（苯并[ d ] [1,3]二恶酚-5-基）乙基）-2-（取代的苯基）乙酰胺的新型骨架7 a -升，这表现出在体外协同抗真菌活性的显着水平。化合物7 d（N-（2-（苯并[ d] [1,3]二恶唑-5-基）乙基）-2-（2-氟苯基）乙酰胺）可显着降低氟康唑相对于耐氟康唑的C的MIC 80值，从128.0μgmL -1降至0.5μgmL -1 。白色念珠菌对人脐静脉内皮细胞的毒性比黄连素低得多。
• Visible-light photocatalyzed oxidative decarboxylation of oxamic acids: a green route to urethanes and ureas
  作者：Govind Goroba Pawar、Frédéric Robert、Etienne Grau、Henri Cramail、Yannick Landais

  DOI：10.1039/c8cc05462b

  日期：——

  based on a photocatalyzed oxidative decarboxylation of oxamic acids is described. The reaction includes in situ generation of an isocyanate from the oxamic acid, using an organic dye as a photocatalyst, a hypervalent iodine reagent as an oxidant and a light source, which trigger the free-radical decarboxylation. This protocol successfully avoids the isolation, purification and storage of carcinogenic

  描述了基于光催化的肟酸的氧化脱羧，可持续的无金属途径生产氨基甲酸酯和尿素的方法。该反应包括使用有机染料作为光催化剂，高价碘试剂作为氧化剂和光源从草酰胺酸原位生成异氰酸酯，从而触发自由基脱羧。该方案成功地避免了致癌的异氰酸酯的分离，纯化和储存，并允许通过一锅法从可商购的来源精制氨基甲酸乙酯和尿素。
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION
  申请人：Hammock D. Bruce

  公开号：US20070117782A1

  公开（公告）日：2007-05-24

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.

  本发明提供了一些化合物，用于治疗高血压的治疗应用中，抑制环氧水解酶。实施本发明的优选化合物类别具有由式1所示的结构，其中Z为氧或硫，W为碳、磷或硫，X和Y各自独立地为氮、氧或硫，而X还可以是碳，R1-R4中至少有一个是氢，当X为氮时，R2为氢，但当X为硫或氧时，R2不存在，当Y为氮时，R4为氢，但当Y为硫或氧时，R4不存在，而R1和R3各自独立地为C1-C20取代或未取代的烷基、环烷基、芳基、酰基或杂环基。
• INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION
  申请人：Kroetz Deanna L.

  公开号：US20110245331A1

  公开（公告）日：2011-10-06

  The invention provides compounds that inhibit epoxide hydrolase in therapeutic applications for treating hypertension. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 wherein Z is oxygen or sulfur, W is carbon phosphorous or sulfur, X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R 1 -R 4 is hydrogen, R 2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R 4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R 1 and R 3 is each independently C 1 -C 20 substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, or heterocyclic.